Hidradenitis Suppurativa and Comorbid Disorder Biomarkers, Druggable Genes, New Drugs and Drug Repurposing—A Molecular Meta-Analysis
December 2021
in “
Pharmaceutics
”
Studysummary This systematic review identified robust biomarkers associated with hidradenitis suppurativa and confirmed potential drugs for repurposing, highlighting key pathogenetic pathways and their links to comorbid disorders. Our plain-language summary of this paper — not a Tressless recommendation.
The systematic review and meta-analysis "Hidradenitis Suppurativa and Comorbid Disorder Biomarkers, Druggable Genes, New Drugs and Drug Repurposing—A Molecular Meta-Analysis" identified the molecular mechanisms of hidradenitis suppurativa/acne inversa (HS) and potential drugs for treatment. The study confirmed three main pathogenic cascades in HS: upregulated inflammation, altered epithelial differentiation, and dysregulated metabolism/hormone signaling. Among the 386 HS-associated differentially expressed genes (DEGs), 105 druggable genes were identified, enriched in various signaling pathways. The study proposed 452 potentially therapeutic compounds, including 120 launched drugs, 178 compounds in clinical studies, and 154 in preclinical evaluation. Of these, 31 drugs were classified as probable repurposing drugs for HS. The study concludes that while adalimumab is the only currently registered drug for HS, numerous other compounds could be repurposed for HS treatment due to their molecular signaling.
